Cel-Sci Corp.

ASE:CVM   3:59:50 PM EDT
8.12
+0.09 (+1.12%)
4:00:00 PM EDT: $8.07 -0.05 (-0.62%)
Products

Cel-Sci’S Multikine Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Versus 48.6%) In The Group Receiving Surgery Plus Radiotherapy

Published: 06/28/2021 13:45 GMT
Cel-Sci Corp. (CVM) - Cel-sci’s Multikine® Immunotherapy Produces Significant 14.1% 5-year Survival Benefit (62.7% Versus 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study.
Cel-sci - Data Indicate Significant Overall Survival Benefit for Patients Who Received Multikine Treatment Regimen Followed by Surgery & Radiotherapy.
Cel-sci - Patients Treated With Multikine Treatment Regimen Followed by Surgery and Radiotherapy Demonstrated Statistically Significant Os Advantage.